Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group

Transplant Proc. 1998 Jun;30(4):1216-8. doi: 10.1016/s0041-1345(98)00216-4.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antilymphocyte Serum / therapeutic use
  • Azathioprine / therapeutic use
  • Cholesterol / blood
  • Cyclosporine / therapeutic use*
  • Drug Therapy, Combination
  • Graft Survival / drug effects*
  • Graft Survival / physiology
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / mortality
  • Kidney Transplantation / physiology
  • Lipoproteins / blood
  • Muromonab-CD3 / therapeutic use
  • Risk Factors
  • Survival Rate
  • Tacrolimus / therapeutic use*
  • Triglycerides / blood

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Lipoproteins
  • Muromonab-CD3
  • Triglycerides
  • Cyclosporine
  • Cholesterol
  • Azathioprine
  • Tacrolimus